what is INVOKANA®?

The first and longest available SGLT2 inhibitor in the US, INVOKANA® is a prescription medication for adults with type 2 diabetes.

INVOKANA® is Proven To Significantly Lower A1C Levels in Adults

INVOKANA® is proven to lower blood sugar (A1C)

Used along with diet and exercise, INVOKANA® is the first in the latest class of diabetes medicines (SGLT2 inhibitors) that’s proven to significantly lower A1C in adults living with type 2 diabetes.

INVOKANA® is a Once-Daily Pill For Type 2 Diabetes

INVOKANA® is a once-daily pill that works around the clock

INVOKANA® is Proven To Show Greater A1C Reductions than JANUVIA®

the 300-mg dose ofINVOKANA® is proven to show greater A1C reductions than Januvia® (sitagliptin)

The starting dose of INVOKANA® is 100 mg. Januvia® is a registered trademark of Merck Sharp & Dohme Corp.

INVOKANA® Can Help Contribute To Weight Loss in Patients

INVOKANA® is not for weight loss, but may help you lose weight—on average 2–3%

Results may vary by dose and when used alone or with certain other diabetes medications.

INVOKANA® May Lower Systolic Blood Pressure in Adults

although it’s not a blood pressure medicine, you may see lower systolic blood pressure with INVOKANA®—on average 3–5 mmHg

Results may vary by dose and when used alone or with metformin, sitagliptin, or insulin.

INVOKANA® Helped People Reach an A1C Goal of <7%

in most clinical trials, the majority of people taking INVOKANA® reached an A1C goal of less than 7%

As recommended by the American Diabetes Association.

Common Side Effects of INVOKANA®

the most common side effects of INVOKANA® include genital yeast infections, urinary tract infections, and changes in urination

watch our commercial


get the facts and start a great INVOKANA® conversation with your doctor with this handy guide


Janssen wants to help you explore cost support options for INVOKANA®

explore savings options